Long-term experience of pegvisomant therapy as a treatment for acromegaly

Clinical Endocrinology

Volumn 71, Issue 1, 2009, Pages 86-91

  Higham, C E ^a   Chung, T T ^b   Lawrance, J ^a   Drake, W M ^b   Trainer, P J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY COMPOSITION; CHOLESTASIS; CHRONIC DRUG ADMINISTRATION; DEATH; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; LIVER FUNCTION TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME;

ACROMEGALY; ADULT; AGED; DRUG TOXICITY; ERGOLINES; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 66949117381     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03469.x     Document Type: Article

References (26)

1. Rajasoorya, C., Holdaway, I.M., Wrightson, P. et al. (1994) Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology, 41, 95 102. (Pubitemid 24232533)
2. Swearingen, B., Barker, F.G. 2nd., Katznelson, L. et al. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3419 3426. (Pubitemid 28500866)
3. Trainer, P.J., Drake, W.M., Katznelson, L. et al. (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine, 342, 1171 1177. (Pubitemid 30211048)
4. van der Lely, A.J., Hutson, R.K., Trainer, P.J. et al. (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet, 358, 1754 1759. (Pubitemid 33152999)
5. Schreiber, I., Buchfelder, M., Droste, M. et al. (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European Journal of Endocrinology, 156, 75 82. (Pubitemid 46553905)
6. Herman-Bonert, V.S., Zib, K., Scarlett, J.A. et al. (2000) Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. Journal of Clinical Endocrinology and Metabolism, 85, 2958 2962.
7. Drake, W.M., Parkinson, C., Akker, S.A. et al. (2001) Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. European Journal of Endocrinology, 145, 451 456. (Pubitemid 32927073)
8. Colao, A., Pivonello, R., Auriemma, R.S. et al. (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumour mass, hypertension and glucose tolerance. European Journal of Endocrinology, 154, 467 477.
9. van der Lely, A.J., Muller, A.F., Janssen, J.A. et al. (2001) Control of tumour size and disease activity during cotreatment with octreotide and the growth hormone receptor anatagonist pegvisomant in an acromegalic patient. Journal of Clinical Endocrinology and Metabolism, 86, 478 481. (Pubitemid 32207445)
10. Jorgenson, J.O.L., Feldt-Rasmussen, U., Frystyk, J. et al. (2005) Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Journal of Clinical Endocrinology and Metabolism, 90, 5627 5631. (Pubitemid 41415468)
11. Feenstra, J., deHerder, W.W., ten Hove, S.M.T.H. et al. (2005) Combined therapy with somatostatin analogs and weekly pegvisomant in active acromegaly. Lancet, 365, 1644 1646. (Pubitemid 40693415)
12. Neggers, S., van Aken, M.O., Janssen, J. et al. (2007) Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. Journal of Clinical Endocrinology and Metabolism, 92, 4598 4601. (Pubitemid 350223432)
13. Harris, P.E., D'Souza, G.A., Good, A.J. et al. (2007) Treatment with pegvisomant alone compared to combination therapy with pegvisomant/octreotide LAR, in acromegaly. In Proceedings of the 89th Annual Meeting of the Endocrine Society (Abstract OR53-3).
14. Rose, D.R. Clemmons, D.R. (2002) Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Hormone and IGF Research, 12, 418 424. (Pubitemid 35378831)
15. Drake, W.M., Rowles, S.V., Roberts, M.E. et al. (2003) Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. European Journal of Endocrinology, 149, 521 527. (Pubitemid 38054695)
16. Barkan, A.L., Burman, P., Clemmons, D.R. et al. (2005) Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. Journal of Clinical Endocrinology and Metabolism, 90, 5684 5691. (Pubitemid 41415476)
17. Biering, H., Saller, B., Bauditz, J. et al. (2006) Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. European Journal of Endocrinology, 154, 213 220. (Pubitemid 43308822)
18. Morrell, D.J., Dadi, H., More, J. et al. (1989) A monoclonal antibody to human insulin-like growth factor-I: characterization, use in radioimmunoassay and effect on the biological activities of the growth factor. Journal of Molecular Endocrinology, 2, 201 206. (Pubitemid 19117456)
19. Drake, W.M., Berney, D.M., Kovacs, K. et al. (2005) Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant. European Journal of Endocrinology, 153, 203 205. (Pubitemid 41167476)
20. Parkinson, C., Burman, P., Messig, M. et al. (2007) Gender, body weight, disease activity and prior radiotherapy influence the response to pegvisomant. Journal of Clinical Endocrinology and Metabolism, 92, 190 195. (Pubitemid 46067530)
21. Freda, P.U., Katznelson, L., van der Lely, A.J. et al. (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 90, 4465 4473. (Pubitemid 41159328)
22. Higham, C.E., Thomas, J., Drake, W.M. et al. (2008) Successful use of once weekly pegvisomant administration in patients with acromegaly. Endocrine Abstracts, 15, 238.
23. Trainer, P.J., Barth, J., Sturgeon, C. et al. (2006) Consensus statement on the standardisation of GH assays. European Journal of Endocrinology, 155, 1 2. (Pubitemid 44103367)
24. Feenstra, J., van Aken, M.O., de Herder, W.W. et al. (2006) Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long acting repeatable attributed to the use of pegvisomant. European Journal of Endocrinology, 152, 61 66.
25. Paisley, A., Roberts, M. Trainer, P. (2007) Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Clinical Endocrinology, 66, 723 726. (Pubitemid 46699549)
26. Bevan, J.S. (2005) Clinical review: the antitumoural effects of somatostatin analog therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism, 90, 1856 1863. (Pubitemid 40464061)